(Q34583699)

English

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

renal carcinoma

1 reference

based on heuristic

inferred from title

Bernard Escudier

9

object named as

Bernard Escudier

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

object named as

Alain Ravaud

3

0 references

Jacques-Olivier Bay

5

object named as

Jacques-Olivier Bay

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Sylvie Negrier

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

David Perol

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Christine Chevreau

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Remy Delva

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Emmanuel Sevin

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Armelle Caty

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

French Immunotherapy Intergroup

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

110

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2468-2477

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

21 January 2018

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

21 January 2018

Chemotherapy in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Factorial design considerations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting quality of life data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23056

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

10.1002/CNCR.23056

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34583699&oldid=2040520280"